Associated Papers
Characterization and functional analysis of BRCA1 and BRCA2 variants in a cohort of 100 unselected patients undergoing germline screening.
Shi Q et al.
Translational Oncology, 2025
40664060 (PubMed )
Supplement: mmc4.xlsx › Clinvar_BRCA1
Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.
Sangree AK et al.
Nature Communications, 2022
35288574 (PubMed )
Supplement: 41467_2022_28884_MOESM9_ESM.xlsx › WT-CBE_library_annotation
Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F et al.
Signal Transduction and Targeted Therapy, 2021
33563892 (PubMed )
Supplement: 41392_2020_412_MOESM17_ESM.xlsx › Supplementary_Table_S16
Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor.
Liu J et al.
Nature Communications, 2020
32978388 (PubMed )
Supplement: 41467_2020_18637_MOESM8_ESM.xlsx › 476MMG_and_476PT
Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Fang YY et al.
Bmc Cancer, 2014
24629067 (PubMed )
Supplement: 1471-2407-14-188-S1.pdf
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
Li D et al.
Cell Cycle (georgetown, Tex.), 2014
25486197 (PubMed )
Supplement: supplement_1.pdf
Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.
Li D et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2013
24321281 (PubMed )
Supplement: 1756-9966-32-102-S1.pdf
Select a paper to view details